Tuesday, June 19, 2018
Company News: Page (1) of 1 - 05/18/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
(May 18, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Manufacturing,Manufacturing/Production,Shipping & Receiving,Manufacturing,Health Care,Canada,USA, Inc.,Medicine,Disease,healthcare,Cancer,Dental,Surgery,Medication,Vitamins/Nutrition,Science,Lifestyle,Medical,Biology,Cancer,Business,Other,
Related Sites: DMN Newswire ,   CEN - Consumer Electronics Net ,   IBN - Business ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines